---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-292003"
form_type: "8-K"
ticker: "CDNA"
cik: "0001217234"
company_name: "CareDx, Inc."
filed_at: "2022-11-23T23:59:59+00:00"
generated_at: "2026-06-21T13:19:05.634149+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.25
calibrated_materiality_score: 0.25
confidence: "high"
source: SEC EDGAR
---

# Director Ralph Snyderman to resign from CareDx board effective Dec 31, 2022

## Summary
- Dr. Ralph Snyderman notified CareDx board of his resignation, effective December 31, 2022.
- Resignation is from the board and all committees; no disagreement with the company cited.
- No replacement director has been announced as of the filing date.

## SEC filing metadata
- accession: 0001193125-22-292003
- form_type: 8-K
- ticker: CDNA
- cik: 0001217234
- company_name: CareDx, Inc.
- filed_at: 2022-11-23T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.25
- calibrated_materiality_score: 0.25
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1217234/000119312522292003/0001193125-22-292003-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1217234/000119312522292003/d318240d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-292003
- JSON: https://secwatch.observer/filing/0001193125-22-292003.json
- Plain text: https://secwatch.observer/filing/0001193125-22-292003.txt

## Key facts
- Executive change
  Ralph Snyderman departed as Director at CareDx, Inc..
  - Action: resigning
  - Role: Director
  source text: On November 21, 2022, Ralph Snyderman, M.D., notified the Board of Directors (the “Board”) of CareDx, Inc. (the “Company”) that he will be resigning from the Board and all committees of the Board, effective as of December 31, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1217234/000119312522292003/0001193125-22-292003-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.